| ACCESS (phase 2b) | Aleniglipron | obesity | 65 | arms |
| ACHIEVE-1 | Orforglipron | t2d | 559 | arms |
| ACHIEVE-2 (vs dapagliflozin) | Orforglipron | t2d | 241 | arms |
| ACHIEVE-4 | Orforglipron | T2D at increased CV risk (86 % established CVD, 38 % CKD), t2d | 2749 | arms, CVOT |
| AMPLITUDE-O | Efpeglenatide | T2D + CVD/CKD | 4076 | CVOT |
| Amycretin oral phase 1 | Amycretin | obesity | 144 | arms |
| Amycretin s.c. phase 1b/2a | Amycretin | obesity | 125 | arms |
| ATTAIN-1 | Orforglipron | obesity | 3127 | arms |
| ATTAIN-2 (obesity + T2D) | Orforglipron | t2d | 1613 | arms |
| ATTAIN-J (Japan) | Orforglipron | obesity | 61 | arms |
| ATTAIN-OSA trial 1 / trial 2 | Orforglipron | Obstructive sleep apnoea + obesity or overweight (no T2D) | 712 | outcomes |
| BGM0504 phase 2 (China, obesity) | BGM0504 | obesity | | arms |
| BGM0504 phase 3 (obesity) | BGM0504 | obesity | | arms |
| China Phase II (obesity, non-diabetic) | HDM1005 | obesity | 243 | arms |
| CT-388 phase 2 | CT-388 | obesity | | arms |
| CT-388-104 (T2D) | CT-388 | t2d | | arms |
| DREAMS-1 | Mazdutide | t2d | 320 | arms |
| DREAMS-2 | Mazdutide | t2d | | arms |
| DREAMS-3 | Mazdutide | t2d | 349 | arms |
| EECOH-1 | Ecnoglutide | t2d | 211 | arms |
| EECOH-2 | Ecnoglutide | t2d | 623 | arms |
| ELAD | Liraglutide | Mild cognitive impairment + T2D | 396 | outcomes |
| ELIXA | Lixisenatide | T2D after ACS | 6068 | CVOT |
| EloraTZP phase 2b (obesity + T2D) | EloraTZP, Eloralintide, Tirzepatide | t2d | | arms |
| ENLIGHT Phase IIb (NCT06921486) | Efsubaglutide alfa (supaglutide) | obesity | 200 | arms |
| ESSENCE (part 1) | Semaglutide | MASH F2–F3 | 800 | outcomes |
| evoke / evoke+ | Semaglutide | Early Alzheimer's disease | 3680 | outcomes |
| EXSCEL | Exenatide | T2D, broad CV risk | 14752 | CVOT |
| FLOW | Semaglutide | CKD + T2D, T2D + CKD | 3533 | CVOT, outcomes |
| GLORY-1 | Mazdutide | obesity | | arms |
| GLORY-2 | Mazdutide | obesity | | arms |
| GRADUAL-1 (NCT06728124) | Bofanglutide (GZR18) | obesity | 640 | arms |
| HARBOR-1 (HRS-7535-303, NCT06904105) | HRS-7535 | obesity | 556 | arms |
| Harmony Outcomes | Albiglutide | T2D + CVD | 9463 | CVOT |
| HDM1002-301 | HDM1002 | obesity | 857 | arms |
| HDM1005 phase 2 (T2D) | HDM1005 | t2d | 220 | arms |
| HDM1702 vs Wegovy (bioequivalence) | HDM1702 | obesity | 462 | arms |
| HRS-4729 phase 1 SAD/MAD, MAD part (NCT06762600) | HRS-4729 | obesity | 60 | arms |
| HRS-7535 phase 2 (add-on to metformin + SGLT2i) | HRS-7535 | t2d | 53 | arms |
| HRS9531-201 (NCT05881837) | Ribupatide (HRS9531) | obesity | 249 | arms |
| HRS9531-203 (NCT06054698) | Ribupatide (HRS9531) | obesity | | arms |
| HRS9531-301 (GEMINI-1, NCT06396429) | Ribupatide (HRS9531) | obesity | 567 | arms |
| HRS9531-T-201 oral ribupatide (NCT06841445) | Ribupatide (HRS9531) | obesity | 166 | arms |
| IMPACT | Pemvidutide | MASH F2–F3 | 212 | outcomes |
| LEADER | Liraglutide | T2D at high CV risk | 9340 | CVOT |
| LIGHTEN (HS-20094-301) | HS-20094 | obesity | 604 | arms |
| MariTide phase 2 (obesity cohort) | MariTide | obesity, t2d | 79 | arms |
| MARITIME-CV | MariTide | Obesity with established CVD | 12800 | ongoing |
| MOMENTUM | Pemvidutide | obesity | 391 | arms |
| OASIS 4 | Semaglutide | obesity | 307 | arms |
| Orforglipron CVOT | Orforglipron | Atherosclerotic CVD, obesity or T2D | 7140 | ongoing |
| OUTSTAND-1 (early T2D, monotherapy) | HRS-7535 | t2d | 284 | arms |
| OUTSTAND-2 (HRS-7535-302, NCT06589765) | HRS-7535 | t2d | 810 | arms |
| PEX168 add-on to metformin phase 3b | PEG-loxenatide | t2d | | arms |
| PEX168 monotherapy phase 3a | PEG-loxenatide | t2d | 361 | arms |
| Phase 2b | Efinopegdutide | MASH F2–F3 | 386 | outcomes |
| Phase 2b CTR20231695 | Bofanglutide (GZR18) | obesity | 64 | arms |
| Phase 2b CTR20232069 (vs semaglutide) | Bofanglutide (GZR18) | t2d | 264 | arms |
| Phase 3 add-on to metformin (Lancet RH-WP 2024;51:101197) | PB-119 | t2d | 310 | arms |
| Phase 3 monotherapy (NCT04504370) | PB-119 | t2d | 137 | arms |
| Phase 3 weight management (ChiCTR1900023428) | Beinaglutide | obesity | 282 | arms |
| Phase III TG103 + metformin vs dulaglutide (EASD 2026) | TG103 | t2d | 211 | arms |
| PIONEER 6 | Semaglutide | T2D at high CV risk | 3183 | CVOT |
| REBUILDING-1 (RAY1225, NCT06254261) | RAY1225 | obesity | 172 | arms |
| REBUILDING-2 (RAY1225, NCT06893016) | RAY1225 | obesity | 641 | arms |
| REDEFINE 1 | CagriSema | obesity | 3417 | arms |
| REDEFINE 2 | CagriSema | t2d | 1206 | arms |
| REDEFINE 3 | CagriSema | Obesity + established CVD | 7101 | ongoing |
| REDEFINE 5 (vs semaglutide 2.4 mg) | CagriSema | obesity | 164 | arms |
| REDEFINE 9 | CagriSema | obesity | | arms |
| REIMAGINE 1 (early T2D) | CagriSema | t2d | 189 | arms |
| REIMAGINE 5 (vs tirzepatide 5 mg) | CagriSema | t2d | | arms |
| Retatrutide phase 2 (obesity) | Retatrutide | obesity | 338 | arms |
| Retatrutide phase 2 (T2D) | Retatrutide | t2d | 281 | arms |
| REWIND | Dulaglutide | T2D, broad CV risk | 9901 | CVOT |
| RGT-075 phase 2b | RGT-075 | obesity | | arms |
| Ribupatide in obesity + PMOS (NCT06595797) | Ribupatide (HRS9531) | obesity | 158 | arms |
| Ribupatide phase 2 (obesity + PMOS) | Ribupatide (HRS9531) | obesity | 158 | arms |
| Ribupatide T2D phase 3 after metformin +/- SGLT2i (NCT06649344) | Ribupatide (HRS9531) | t2d | | arms |
| SELECT | Semaglutide | Obesity + established CVD, no diabetes | 17604 | CVOT |
| Shining-1 (T2D) | RAY1225 | t2d | 231 | arms |
| SLIMMER | Ecnoglutide | obesity | 664 | arms |
| SLIMMER-UP-SWITCH (interim) | Ecnoglutide | obesity | 163 | arms |
| SOLSTICE (NCT06579105) | AZD5004 (ECC5004) | t2d | 406 | arms |
| SOUL | Semaglutide | T2D + CVD/CKD | 9650 | CVOT |
| STEP 1 | Semaglutide | obesity | 1961 | arms |
| STEP 2 | Semaglutide | t2d | 1210 | arms |
| STEP 9 | Semaglutide | Knee osteoarthritis + obesity | 407 | outcomes |
| STEP UP | Semaglutide | obesity | 1407 | arms |
| STEP-HFpEF | Semaglutide | HFpEF + obesity | 529 | outcomes |
| STEP-HFpEF DM | Semaglutide | HFpEF + obesity + T2D | 616 | outcomes |
| SUMMIT | Tirzepatide | HFpEF + obesity | 731 | CVOT, outcomes |
| SUPER 2 (NCT04998032), phase 3 stage | Efsubaglutide alfa (supaglutide) | t2d | 171 | arms |
| SURMOUNT-1 | Tirzepatide | obesity | 2539 | arms |
| SURMOUNT-2 | Tirzepatide | t2d | 938 | arms |
| SURMOUNT-5 (head-to-head) | Tirzepatide | obesity | 751 | arms |
| SURMOUNT-MMO | Tirzepatide | Obesity, morbidity and mortality | 15374 | ongoing |
| SURMOUNT-OSA | Tirzepatide | Obstructive sleep apnoea + obesity | 469 | outcomes |
| SURPASS-CVOT | Tirzepatide | T2D + established ASCVD | 13299 | CVOT |
| Survodutide phase 2 (obesity) | Survodutide | obesity | 387 | arms |
| Survodutide phase 2 MASH | Survodutide | MASH F1–F3 | 293 | outcomes |
| SUSTAIN-6 | Semaglutide | T2D at high CV risk | 3297 | CVOT |
| SYNCHRONIZE-1 | Survodutide | obesity | 242 | arms |
| SYNCHRONIZE-2 (obesity + T2D) | Survodutide | t2d | | arms |
| SYNCHRONIZE-CVOT | Survodutide | Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD), obesity | 5530 | arms, CVOT |
| SYNERGY-NASH | Tirzepatide | MASH F2–F3 | 190 | outcomes |
| TG103 phase 3 vs dulaglutide (T2D) | TG103 | t2d | | arms |
| TRANSCEND-T2D-1 (T2D monotherapy) | Retatrutide | t2d | 537 | arms |
| TRANSCEND-T2D-2 (vs semaglutide 2 mg) | Retatrutide | t2d | | arms |
| TRIUMPH-1 | Retatrutide | obesity | 584 | arms |
| TRIUMPH-1-OSA / TRIUMPH-2-OSA | Retatrutide | Obstructive sleep apnoea + obesity (with or without T2D) | 691 | outcomes |
| TRIUMPH-2 (obesity + T2D) | Retatrutide | t2d | | arms |
| TRIUMPH-4 (obesity + knee osteoarthritis) | Retatrutide | obesity | 148 | arms |
| TRIUMPH-4 / TRIUMPH-1-OA | Retatrutide | Knee osteoarthritis + obesity | 1019 | outcomes |
| TRIUMPH-OUTCOMES | Retatrutide | Obesity + CVD | 10000 | ongoing |
| UBT251 phase 2 (obesity) | UBT251 | obesity | | arms |
| UBT251 phase 2 (T2D) | UBT251 | t2d | | arms |
| UBT251 phase 2 obesity China (NCT07177469) | UBT251 | obesity | 205 | arms |
| UBT251 phase 2 T2D China (NCT07163624) | UBT251 | t2d | 211 | arms |
| US phase 2 (NCT06124807) | Mazdutide | obesity | 179 | arms |
| US Phase 2 (NCT06737042) | Bofanglutide (GZR18) | obesity | 326 | arms |
| VENTURE (phase 2, s.c.) | VK2735 | obesity | 36 | arms |
| VENTURE-Oral (phase 2) | VK2735 | obesity | 40 | arms |
| VISTA (NCT06579092) | AZD5004 (ECC5004) | obesity | 310 | arms |
| Zenagamtide s.c. phase 2 (T2D) | Amycretin | t2d | 38 | arms |
| ZUPREME-1 | Petrelintide | obesity | | arms |
| ZUPREME-2 (obesity + T2D) | Petrelintide | t2d | | arms |